Drug
Ibodutant
Ibodutant: highest development phase Phase 3, developed by Menarini. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Menarini
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ibodutant 10 mg NCT02320318 | Phase 3 | Irritable Bowel Syndrome With Diarrhea |
| Ibodutant NCT00761007 | Phase 2 | Irritable Bowel Syndrome |
| Ibodutant NCT01303224 | Phase 2 | Irritable Bowel Syndrome With Diarrhea |
Latest
No recent events.
Follow Ibodutant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.